CEL-SCI Corporation

CEL-SCI Corporation is a late-stage biotechnology company focused on developing immunotherapies for the treatment of cancer, autoimmune, and infectious diseases. The company's lead investigational therapy, Multikine, is currently being developed as a potential first-line treatment for advanced primary head and neck cancer. Multikine is unique in that it is administered before standard of care therapies (surgery, radiation, and chemotherapy) with the goal of boosting the patient's immune system while it is still relatively intact and able to mount a strong anti-tumor response. This approach contrasts with most other cancer immunotherapies, which are typically used after conventional treatments have failed.

CEL-SCI also possesses a platform technology called LEAPS, which is being developed for the treatment of rheumatoid arthritis and other autoimmune diseases. LEAPS utilizes synthetic peptides to stimulate antigen-specific immune responses in T-cells, potentially enhancing the body's natural defense system against disease. CEL-SCI's research and development efforts are guided by a commitment to developing innovative therapies that address unmet medical needs and create real value for stakeholders.

CEL-SCI offers a competitive benefits package that includes medical, dental, and vision insurance, long-term disability, life and AD&D insurance, a 401(k) plan with company stock matching, flexible spending accounts (FSA), stock option plans, tuition reimbursement, and vacation and sick leave.

CEL-SCI Corporation is a biotechnology company dedicated to researching and developing immunotherapy products for the treatment of cancer, autoimmune, and infectious diseases. They are driven by the mission to improve patient outcomes by harnessing the body's natural defense system, the immune system, to fight disease. Their approach emphasizes developing innovative therapies that address unmet medical needs and creating real value for stakeholders through rigorous, data-driven research.

CEL-SCI Corporation promotes a culture of scientific rigor, innovation, and perseverance. They value data-driven decision making and a "no shortcuts" approach to drug development. The company emphasizes ethical conduct, open communication, and rewarding bold innovation. They are dedicated to creating real value for their stakeholders by developing therapies that address unmet medical needs, and believe that doing good can also make money.

CEL-SCI Corporation is proud to be an equal opportunity employer, extending employment to both women and men from culturally diverse backgrounds. They respect and value individual differences, recognizing each employee as an integral member of the company. Their workforce reflects these values, celebrating the individuals who make up their growing team.